Marie Dell'Aquila

Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of b-cell chronic lymphocytic leukemia

CONTEXT Chromosomal abnormalities (namely 13q, 17p, and 11q deletions) have prognostic implications and are recurrent in chronic lymphocytic leukemia (CLL), suggesting that they are involved in a common pathogenetic pathway; however, the molecular mechanism through which chromosomal abnormalities affect the pathogenesis and outcome of CLL is unknown. OBJECTIVE To determine whether the microRNA miR-15a/miR-16-1 cluster (located at 13q), tumor protein p53 (TP53, located at 17p), and miR-34b/miR-34c cluster (located at 11q) are linked in a molecular pathway that explains the pathogenetic and prognostic implications (indolent vs aggressive form) of recurrent 13q, 17p, and 11q deletions in CLL. DESIGN, SETTING, AND PATIENTS CLL Research Consortium institutions provided blood samples from untreated patients (n = 206) diagnosed with B-cell CLL between January 2000 and April 2008. All samples were evaluated for the occurrence of cytogenetic abnormalities as well as the expression levels of the miR-15a/miR-16-1 cluster, miR-34b/miR-34c cluster, TP53, and zeta-chain (TCR)-associated protein kinase 70 kDa (ZAP70), a surrogate prognostic marker of CLL. The functional relationship between these genes was studied using in vitro gain- and loss-of-function experiments in cell lines and primary samples and was validated in a separate cohort of primary CLL samples. MAIN OUTCOME MEASURES Cytogenetic abnormalities; expression levels of the miR-15a/miR-16-1 cluster, miR-34 family, TP53 gene, downstream effectors cyclin-dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A) and B-cell CLL/lymphoma 2 binding component 3 (BBC3), and ZAP70 gene; genetic interactions detected by chromatin immunoprecipitation. RESULTS In CLLs with 13q deletions the miR-15a/miR-16-1 cluster directly targeted TP53 (mean luciferase activity for miR-15a vs scrambled control, 0.68 relative light units (RLU) [95% confidence interval {CI}, 0.63-0.73]; P = .02; mean for miR-16 vs scrambled control, 0.62 RLU [95% CI, 0.59-0.65]; P = .02) and its downstream effectors. In leukemic cell lines and primary CLL cells, TP53 stimulated the transcription of miR-15/miR-16-1 as well as miR-34b/miR-34c clusters, and the miR-34b/miR-34c cluster directly targeted the ZAP70 kinase (mean luciferase activity for miR-34a vs scrambled control, 0.33 RLU [95% CI, 0.30-0.36]; P = .02; mean for miR-34b vs scrambled control, 0.31 RLU [95% CI, 0.30-0.32]; P = .01; and mean for miR-34c vs scrambled control, 0.35 RLU [95% CI, 0.33-0.37]; P = .02). CONCLUSIONS A microRNA/TP53 feedback circuitry is associated with CLL pathogenesis and outcome. This mechanism provides a novel pathogenetic model for the association of 13q deletions with the indolent form of CLL that involves microRNAs, TP53, and ZAP70.

t(4;22)(q12;q11.2) involving presumptive platelet-derived growth factor receptor A and break cluster region in a patient with mixed phenotype acute leukemia

The patient is a 45-year-old woman with a history of breast cancer who had been treated 1 year ago with radiation and chemotherapy. Flow cytometric analysis of bone marrow aspirate revealed 81% blasts positive for CD4, CD11c (partial), CD13, CD19 (partial), cytoplasmic CD22, CD34, CD36, CD45, cytoplasmic CD79a, CD117 (partial), HLA-DR, and terminal deoxynucleotide transferase, consistent with a mixed phenotype acute leukemia (B/myeloid lineage). Conventional karyotypic analysis revealed a t(4;22)(q12;q11.2) in 12 of 13 cells analyzed. Fluorescence in situ hybridization analysis using a dual-color, dual-fusion break cluster region/ABL probe set showed no break cluster region/ABL translocation but an extra break cluster region signal in 85% (170/200) of cells, consistent with a translocation involving the break cluster region gene at 22q11.2. A FIP1L1/CHIC2/platelet-derived growth factor receptor α deletion/fusion probe showed signal separation in 96.5% (193/200) of interphase nuclei. Reverse transcriptase-polymerase chain reaction using sense break cluster region primers and an antisense platelet-derived growth factor receptor α primer resulted in a product of approximately 590 base pairs, consistent with the presence of a break cluster region/platelet-derived growth factor receptor α fusion gene. Because of the presumptive platelet-derived growth factor receptor α translocation and its sensitivity to tyrosine-kinase inhibitor, the patient was treated with imatinib mesylate, cytarabine, and idarubicin as induction and maintenance therapy; and she has remained free of disease for 5 months since the initial diagnosis.

JAK2 double minutes with resultant simultaneous amplification of JAK2 and CD274 in a therapy-related myelodysplastic syndrome evolving into an acute myeloid leukaemia

Bachas, C., Schuurhuis, G.J., Hollink, I.H., Kwidama, Z.J., Goemans, B.F., Zwaan, C.M., van den Heuvel-Eibrink, M.M., de Bont, E.S., Reinhardt, D., Creutzig, U., de Haas, V., Assaraf, Y.G., Kaspers, G.J. & Cloos, J. (2010) High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine. Blood, 116, 2752–2758. Balgobind, B.V., Raimondi, S.C., Harbott, J., Zimmermann, M., Alonzo, T.A., Auvignon, A., Beverloo, H.B., Chang, M., Creutzig, U., Dworzak, M.N., Forestier, E., Gibson, B., Hasle, H., Harrison, C.J., Heerema, N.A., Kaspers, G.J., Leszl, A., Litvinko, N., Lo Nigro, L., Morimoto, A., Perot, C., Pieters, R., Reinhardt, D., Rubnitz, J.E., Smith, F.O., Stary, J., Stasevich, I., Strehl, S., Taga, T., Tomizawa, D., Webb, D., Zemanova, Z., Zwaan, C.M. & van den Heuvel-Eibrink, M.M. (2009) Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood, 114, 2489–2496. Balgobind, B.V., Hollink, I.H., Arentsen-Peters, S.T., Zimmermann, M., Harbott, J., Beverloo, H.B., von Bergh, A.R., Cloos, J., Kaspers, G.J., de Haas, V., Zemanova, Z., Stary, J., Cayuela, J.M., Baruchel, A., Creutzig, U., Reinhardt, D., Pieters, R., Zwaan, C.M. & van den HeuvelEibrink, M.M. (2011) Integrative analysis of type-I and type-II aberrations underscore the genetic heterogeneity of pediatric acute myeloid leukemia. Haematologica, 96, 1478–1497. Coenen, E.A., Zwaan, C.M., Stary, J., Baruchel, A., de Haas, V., Stam, R.V., Reinhardt, D., Kaspers, G.J., Arentsen-Peters, S.T., Meyer, C., Marschalek, R., Lo Nigro, L., Dworzak, M., Pieters, R. & van den Heuvel-Eibrink, M.M. (2014) Unique BHLHB3 overexpression in pediatric acute myeloid leukemia with t(6;11)(q27;q23). Leukemia, 96, 1478–1487. Emerenciano, M., Barbosa, T. da C., de Almeida Lopes, B., Meyer, C., Marschalek, R. & Pombo-deOliveira, M.S. (2015) Subclonality and prenatal origin of RAS mutations in KMT2A(MLL)rearranged infant acute lymphoblastic leukaemia. British Journal of Haematology, 170, 268–271. Liang, D.C., Chen, S.H., Liu, H.C., Yang, C.P., Yeh, T.C., Jaing, T.H., Hung, I.J., Hou, J.Y., Lin, T.H., Lin, C.H. & Shih, L.Y. (2018) Mutational status of NRAS, KRAS and PTPN11 genes is associated with genetic/cytogenetic features in children with B-precursor acute lymphoblastic leukemia. Pediatric Blood & Cancer, 65, e26786. Meshinchi, S., Stirewalt, D.L., Alonzo, T.A., Zhang, Q., Sweetser, D.A., Woods, W.G., Bernstein, I.D., Arceci, R.J. & Radich, J.P. (2003) Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia. Blood, 102, 1474–1479. Pession, A., Masetti, R., Rizzari, C., Putti, M.C., Casale, F., Fagioli, F., Luciani, M., Lo Nigro, L., Menna, G., Micalizzi, C., Santoro, N., Testi, A.M., Zecca, M., Biondi, A., Pigazzi, M., Rutella, S., Rondelli, R., Basso, G. & Locatelli, F. (2013) Results of the AIEOP-AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood, 122, 170–178. Stieglitz, E., Taylor-Weiner, A.N., Chang, T.Y., Gelston, L.C., Wang, Y.D., Mazor, T., Esquivel, E., Yu, A., Seepo, S., Olsen, S., Rosenberg, M., Archambeault, S.L., Abusin, G., Beckman, K., Brown, P.A., Briones, M., Carcamo, B., Cooper, T., Dahl, G.V., Emanuel, P.D., Fluchel, M.N., Goyal, R.K., Hayashi, R.J., Hitzler, J., Hugge, C., Liu, Y.L., Messinger, Y.H., Mahoney, D.H. Jr, Monteleone, P., Nemecek, E.R., Roehrs, P.A., Schore, R.J., Stine, K.C., Takemoto, C.M., Toretsky, J.A., Costello, J.F., Olshen, A.B., Stewart, C., Li, Y., Ma, J., Gerbing, R.B., Alonzo, T.A., Getz, G., Gruber, T., Golub, T., Stegmaier, K. & Loh, M.L. (2015) The genomic landscape of juvenile myelomonocytic leukemia. Nature Genetics, 47, 1326–1333. Wiemels, J.L., Kang, M., Chang, J.S., Zeng, L., Kouyoumji, C., Zhang, L., Smith, M.T., Scelo, G., Metayer, C., Buffler, P. & Wiencke, J.K. (2010) Backtracking RAS mutations in high hyperdiploid childhood acute lymphoblastic leukemia. Blood Cells, Molecules and Diseases, 45, 186–191.